Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

I-ATTAC: Improved Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma

NCT03927222 is registered in ClinicalTrials.gov with Mustafa Khasraw, MBChB, MD, FRCP, FRACP as lead sponsor.

NCT NCT03927222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03927222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
I-ATTAC: Improved Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2019
Completion date
February 10, 2023
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma